<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136653</url>
  </required_header>
  <id_info>
    <org_study_id>MP0250-CP201</org_study_id>
    <secondary_id>2016-002771-10</secondary_id>
    <nct_id>NCT03136653</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Partners AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety, tolerability, pharmacokinetics&#xD;
      (PK), immunogenicity and efficacy of MP0250 in combination with bortezomib + dexamethasone in&#xD;
      patients with refractory and relapsed multiple myeloma (RRMM).&#xD;
&#xD;
      MP0250 is a multi-DARPin® drug candidate with three specificities, able to simultaneously&#xD;
      neutralize the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth&#xD;
      factor (HGF) and also to bind to human serum albumin (HSA) to give an increased plasma&#xD;
      half-life and potentially enhanced tumor penetration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">October 12, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Overall Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the number of participants achieving a complete response (CR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: ORR</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the number of participants achieving a confirmed, stringent complete response (sCR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experienced One or More Treatment-Emergent SAEs</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3 Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Clinical Significant Change from Baseline in Laboratory Results</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Clinically Significant Change from Baseline in Vital Signs</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Results</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Positive Anti-drug Antibody (ADA) Result</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of Anti-drug Antibodies (ADA)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Anti-drug Antibodies</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>DOR is defined as the duration from first observation of partial response (PR) or better until disease progression, or death from myeloma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is determined as the time from first study treatment until progression or death from myeloma.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Single arm Study MP0250 plus BOR + DEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study of MP0250 plus bortezomib + dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MP0250 plus BOR+DEX</intervention_name>
    <description>6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.&#xD;
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Single arm Study MP0250 plus BOR + DEX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with MM who have received:&#xD;
&#xD;
               -  Part 1 ≥2 lines of therapy (including bortezomib and an IMiD) and have shown no&#xD;
                  response (i.e. stable disease) to, have progressed on the most recent treatment&#xD;
                  or have progressed within 60 days of the most recent therapy&#xD;
&#xD;
               -  Part 2 ≥2 lines of prior therapy that included a proteasome inhibitor&#xD;
                  (bortezomib, carfilzomib or both) and an IMiD (thalidomide, lenalidomide and/or&#xD;
                  pomalidomide) either alone or in combination and a response no better than SD&#xD;
                  lasting at least 4 months on a bortezomib- or carfilzomib-based regimen as last&#xD;
                  line of therapy or progression on treatment or within 60 days of stopping a&#xD;
                  bortezomib- or carfilzomib-based regimen as last line of therapy. Note: For&#xD;
                  transplant-eligible patients enrolled to Part 1 or Part 2, induction plus&#xD;
                  conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen.&#xD;
&#xD;
          2. Presence of a measurable disease with at least one of the following criteria:&#xD;
&#xD;
               -  Serum M protein ≥0.5 g/dL, or&#xD;
&#xD;
               -  Urine M protein ≥200 mg/24 h, or&#xD;
&#xD;
               -  Involved serum free light chain (FLC) levels &gt;100 mg/L and abnormal kappa/lambda&#xD;
                  (κ/λ) ratio in patients without detectable serum or urine M protein, or&#xD;
&#xD;
               -  For patients with immunoglobulin A (IgA) myeloma whose disease can only be&#xD;
                  reliably measured by quantitative immunoglobulin measurement, a serum IgA level&#xD;
                  ≥0.5g/dL.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (0 to 1)&#xD;
&#xD;
          4. Life expectancy &gt;3 months&#xD;
&#xD;
          5. Adequate hepatic function at Screening, with aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) &lt;3x ULN and total bilirubin &lt;2 x upper limit of normal&#xD;
             (ULN). For patients with Gilbert's syndrome (Gilbert-Meulengracht syndrome), higher&#xD;
             bilirubin of 5 x ULN is acceptable&#xD;
&#xD;
          6. Absolute neutrophil count (ANC) ≥1000/mm3 at Screening. Screening ANC must be&#xD;
             independent of growth factor support for ≥1 week&#xD;
&#xD;
          7. Hemoglobin ≥8.0 g/dL at Screening. Use of erythropoietic stimulating factors and red&#xD;
             blood cell (RBC) transfusions per institutional guidelines is allowed, however most&#xD;
             recent RBC transfusion must not have been done within 7 days prior to obtaining&#xD;
             screening hemoglobin&#xD;
&#xD;
          8. Platelet count ≥50 000/mm3 at Screening. Patients must not have received platelet&#xD;
             transfusions for at least 1 week prior to obtaining the screening platelet count&#xD;
&#xD;
          9. Calculated or measured creatinine clearance (CrCl) of ≥ 45 mL/min at Screening based&#xD;
             on the Cockcroft and Gault formula&#xD;
&#xD;
         10. Serum albumin concentration ≥ 25 g/L. Note: Patients with lower levels of serum&#xD;
             albumin at baseline may receive albumin supplementation to comply with this criterion&#xD;
&#xD;
         11. Males and females ≥18 years of age&#xD;
&#xD;
         12. Male Participants: A male participant must agree to use a highly effective&#xD;
             contraception&#xD;
&#xD;
         13. Female Participants: A female participant is eligible to participate if she is not&#xD;
             pregnant, not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP) OR&#xD;
&#xD;
               2. A WOCBP who agrees to follow contraceptive guidance from the Screening visit,&#xD;
                  during the treatment period and for at least 3 months after the last dose of&#xD;
                  study treatment&#xD;
&#xD;
         14. Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the following diseases:&#xD;
&#xD;
               -  Monoclonal gammopathy of undetermined significance (MGUS) of non- immunoglobulin&#xD;
                  (Ig)M and IgM subtypes,&#xD;
&#xD;
               -  Light chain MGUS,&#xD;
&#xD;
               -  Solitary plasmacytoma (alone or with minimal marrow involvement),&#xD;
&#xD;
               -  Systemic Ig light chain amyloidosis,&#xD;
&#xD;
               -  Waldenstrom's Macroglobulinemia,&#xD;
&#xD;
               -  Myelodysplastic syndrome,&#xD;
&#xD;
               -  Plasma cell leukemia defined as a plasma cell count &gt;2000/mm3&#xD;
&#xD;
               -  Polyneuropathy, organomegaly endocrinopathy, monoclonal protein, and skin changes&#xD;
                  (POEMS) syndrome&#xD;
&#xD;
          2. Peripheral neuropathy Grade 2 or higher at Screening or patients with a history of&#xD;
             Grade 3/4 neuropathy or Grade 2 with pain&#xD;
&#xD;
          3. Prior or concurrent malignancy, except for: Adequately treated basal cell or squamous&#xD;
             cell skin cancer, carcinoma in-situ of the cervix or breast or very low and low risk&#xD;
             prostate cancer in active surveillance or any other cancer from which the patient has&#xD;
             been disease-free for &gt;5 years&#xD;
&#xD;
          4. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),&#xD;
             symptomatic cardiac ischemia, or conduction abnormalities uncontrolled by conventional&#xD;
             intervention. Myocardial infarction within 6 months prior to screening&#xD;
&#xD;
          5. Uncontrolled hypertension (defined as systolic blood pressure (SBP) &gt;150 mm Hg&#xD;
             diastolic blood pressure (DBP) &gt;100 mm Hg despite antihypertensive medication)&#xD;
&#xD;
          6. Stroke, or transient ischemic attack within 6 months of Screening, clinically&#xD;
             significant bleeding and vascular disease&#xD;
&#xD;
          7. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the&#xD;
             past 6 months&#xD;
&#xD;
          8. Significant concurrent, uncontrolled medical condition including, but not limited to,&#xD;
             severe wound healing complication, renal (except related to MM), hepatic,&#xD;
             hematological except MM, gastrointestinal, endocrine, pulmonary, neurological,&#xD;
             cerebral or psychiatric disease&#xD;
&#xD;
          9. Acute active infection requiring systemic antibiotics, antiviral (except antiviral&#xD;
             therapy directed at hepatitis B) or antifungal agents within 14 days prior to&#xD;
             screening&#xD;
&#xD;
         10. Clinical signs of or documented leptomeningeal or cerebral involvement of MM&#xD;
&#xD;
         11. Treatment with ixazomib as last line of therapy in Part 2&#xD;
&#xD;
         12. Therapy with approved or investigational anticancer therapeutics within 21 days (or in&#xD;
             the case of nitrosureas, within 6 weeks) prior to treatment (except anti-myeloma&#xD;
             treatment with a carfilzomib- or bortezomib-based regimen in Part 2) Note: Patients&#xD;
             must have recovered from pre-existing, treatment-related adverse events to Grade 1 or&#xD;
             lower&#xD;
&#xD;
         13. Autologous stem cell transplantation (ASCT) within 12 weeks before the date of&#xD;
             enrollment&#xD;
&#xD;
         14. Prior allogeneic stem cell transplantation with active graft-versus-host-disease&#xD;
&#xD;
         15. Major surgery within 21 days prior to Screening&#xD;
&#xD;
         16. Immunotherapy within 21 days prior to Screening&#xD;
&#xD;
         17. Newly initiated therapy with bisphosphonate or RANKL (within two months prior to&#xD;
             Screening). Patients on stable regimen with bisphosphonate or receptor activator of&#xD;
             nuclear kappa-B ligand (RANKL)-inhibitor therapy over 2 months can continue these&#xD;
             treatments at the same dose. No new therapy with bisphosphonate/RANKL inhibitor is&#xD;
             allowed during the study&#xD;
&#xD;
         18. Radiation therapy within 2 months of Cycle 1, Day 1 is not permitted Except for local&#xD;
             low-dose, palliative radiation to bone lesions for pain control.&#xD;
&#xD;
         19. Patients who have received treatment with any non-marketed product within 21 days&#xD;
             prior to treatment start&#xD;
&#xD;
         20. Current participation in any other interventional clinical study&#xD;
&#xD;
         21. Patients known or suspected of not being able to comply with a study protocol (e.g.&#xD;
             due to alcoholism, drug dependency or psychological disorder)&#xD;
&#xD;
         22. Known infection with human immunodeficiency virus or serologic status reflecting&#xD;
             active hepatitis B or hepatitis C virus infection as follows:&#xD;
&#xD;
               -  Not receiving or not responding to anti-viral therapy.&#xD;
&#xD;
               -  HCV RNA detected&#xD;
&#xD;
         23. Patients with contraindication to dexamethasone or bortezomib according to the&#xD;
             applicable local product label&#xD;
&#xD;
         24. Known hypersensitivity to components of the investigational product, for example,&#xD;
             histidine buffer or the Tween diluent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanusch Krankenhaus Wiener Gebietskrankenkasse</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskliniken Salzburg Saint Johanns-Spital</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <state>Jihormoravsky Krav</state>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní Nemocnice Ostrava</name>
      <address>
        <city>Ostrava - Poruba</city>
        <state>Severomoravsky KRAJ</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg-Altona</city>
        <state>Hamburg</state>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej Zespół Szpitali Miejskich</name>
      <address>
        <city>Chorzów</city>
        <state>Slaskie</state>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Opolu</name>
      <address>
        <city>Opole</city>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DARPin</keyword>
  <keyword>MP0250</keyword>
  <keyword>VEGF</keyword>
  <keyword>HGF</keyword>
  <keyword>RRMM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

